Clinical Trial: A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07680829) titled 'A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia' on June 24.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus lifestyle management. Eligible participants complete a screening run-in period, then randomize equally to three treatment groups: two active DR10624 subcutaneous injection groups and one placebo group. All subjects maintain fixed oral background lipid therapy throughout long-term double-blind treatment,...